Prelude Therapeutics (PRLD) Times Interest Earned (2019 - 2026)
Prelude Therapeutics (PRLD) posted Times Interest Earned of -$0.7 for Q1 2026, up 97.04% sequentially from -$23.63 in Q4 2025, and up 53.62% YoY from -$0.46 in Q1 2025.
Prelude Therapeutics (PRLD) Times Interest Earned (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Times Interest Earned for 8 years, with the latest figure at -$0.7 in Q1 2026.
- Quarterly Times Interest Earned rose 53.62% year-over-year to -$0.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.15 (up 31.96% YoY) and the FY2025 annual result came in at -$0.49, up 35.49% from the prior year.
- Times Interest Earned rose to -$0.7 in Q1 2026 per PRLD's latest filing, from -$23.63 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.3 in Q4 2022 and troughed at -$77.55 in Q4 2023.
- A 5-year average of -$11.95 and a median of -$2.51 in 2022 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2024: Times Interest Earned plunged 25696.43% in 2023, then surged 93.64% in 2024.
- Over 5 years, Times Interest Earned stood at -$0.3 in 2022, then plunged by 25696.43% to -$77.55 in 2023, then increased by 18.0% to -$63.59 in 2024, then soared by 62.83% to -$23.63 in 2025, then soared by 97.04% to -$0.7 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$0.7, -$23.63, and -$0.95 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | -0.41 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.41 |
| Mar 31, 2026 | -0.70 |
| Dec 31, 2025 | -23.63 |
| Sep 30, 2025 | -0.95 |
| Jun 30, 2025 | -1.45 |
| Mar 31, 2025 | -1.51 |
| Dec 31, 2024 | -63.59 |
| Sep 30, 2024 | -0.82 |
| Jun 30, 2024 | -0.87 |
| Mar 31, 2024 | -0.79 |
| Dec 31, 2023 | -77.55 |
| Sep 30, 2023 | -12.84 |
| Jun 30, 2023 | -6.00 |
| Mar 31, 2023 | -3.20 |
| Dec 31, 2022 | -0.30 |
| Sep 30, 2022 | -2.51 |
| Jun 30, 2022 | -3.83 |
| Mar 31, 2022 | -2.68 |
| Dec 31, 2021 | -0.44 |
| Sep 30, 2021 | -0.22 |